Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.63 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 8/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271394 | 1.00 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL2230694 | 1.00 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL6043443 | 0.89 | PPARA (0.57) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL27422193 | 0.89 | PPARA (0.65) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL6043704 | 0.87 | PPARA (0.55) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL6043402 | 0.87 | PPARA (0.55) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL22980587 | 0.86 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL22980586 | 0.86 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL28763859 | 0.84 | PPARA (0.60) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL22990674 | 0.84 | PPARA (0.60) | PPARACTSSPPARGCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4455129-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2024-10-30 | — | — | EP | disclosed |
| EP-4010329-B9 | DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-4010329-B9 | DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| WO-2023125918-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125918-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-4010329-B1 | DEUTERATED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PPARA 2836/4885CTSS 3741/4885PPARG 3121/4885 |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PPARA 2836/4885CTSS 3741/4885PPARG 3121/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | PPARA 2836/4885CTSS 3741/4885PPARG 3121/4885 |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | PPARA 1493/4885CTSS 3642/4885PPARG 1882/4885 |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | POLQ, POLB, POLM | PPARA 2214/4885CTSS 3283/4885PPARG 2667/4885 |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | PPARA 740/4885CTSS 1839/4885PPARG 253/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PPARA 2836/4885CTSS 3741/4885PPARG 3121/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PPARA 1493/4885CTSS 3642/4885PPARG 1882/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | PPARA 483/4885CTSS 1753/4885PPARG 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.